Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

被引：19

作者：

Ahn, M. ^{[1
]}

Camidge, D. R. ^{[2
]}

Tiseo, M. ^{[3
]}

Reckamp, K. ^{[4
]}

Hansen, K. ^{[5
]}

Kim, S. ^{[6
]}

Huber, R. ^{[7
]}

West, H. ^{[8
]}

Groen, H. ^{[9
,10
]}

Hochmair, M. ^{[11
]}

Leighl, N. ^{[12
]}

Gettinger, S. ^{[13
]}

Langer, C. ^{[14
]}

Paz-Ares, L. ^{[15
]}

Smit, E. ^{[16
]}

Kim, E. ^{[17
]}

Reichmann, W. ^{[18
]}

Kerstein, D. ^{[18
]}

Kim, D. ^{[19
]}

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Univ Colorado, Canc Ctr, Aurora, CO USA

[3] Univ Hosp Parma, Med Oncol, Parma, Italy

[4] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Asan Med Ctr, Seoul, South Korea

[7] Univ Hosp Munich, Thorac Oncol Ctr Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Groningen, Groningen, Netherlands

[10] Univ Med Ctr Groningen, Groningen, Netherlands

[11] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[12] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[13] Yale Canc Ctr, New Haven, CT USA

[14] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[15] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[16] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[17] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA

[18] Ariad Pharmaceut Inc, Cambridge, MA USA

[19] Seoul Natl Univ Hosp, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

ALK; brigatinib; NSCLC;

D O I：

10.1016/j.jtho.2017.09.350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 05.05

引用

页码：S1755 / S1756

页数：2